Literature DB >> 20727668

Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Giovanni Lughezzani1, Alberto Briganti, Pierre I Karakiewicz, Michael W Kattan, Francesco Montorsi, Shahrokh F Shariat, Andrew J Vickers.   

Abstract

CONTEXT: Numerous predictive and prognostic tools have recently been developed for risk stratification of prostate cancer (PCa) patients who are candidates for or have been treated with radical prostatectomy (RP).
OBJECTIVE: To critically review the currently available predictive and prognostic tools for RP patients and to describe the criteria that should be applied in selecting the most accurate and appropriate tool for a given clinical scenario. EVIDENCE ACQUISITION: A review of the literature was performed using the Medline, Scopus, and Web of Science databases. Relevant reports published between 1996 and January 2010 identified using the keywords prostate cancer, radical prostatectomy, predictive tools, predictive models, and nomograms were critically reviewed and summarised. EVIDENCE SYNTHESIS: We identified 16 predictive and 22 prognostic validated tools that address a variety of end points related to RP. The majority of tools are prediction models, while a few consist of risk-stratification schemes. Regardless of their format, the tools can be distinguished as preoperative or postoperative. Preoperative tools focus on either predicting pathologic tumour characteristics or assessing the probability of biochemical recurrence (BCR) after RP. Postoperative tools focus on cancer control outcomes (BCR, metastatic progression, PCa-specific mortality [PCSM], overall mortality). Finally, a novel category of tools focuses on functional outcomes. Prediction tools have shown better performance in outcome prediction than the opinions of expert clinicians. The use of these tools in clinical decision-making provides more accurate and highly reproducible estimates of the outcome of interest. Efforts are still needed to improve the available tools' accuracy and to provide more evidence to further justify their routine use in clinical practice. In addition, prediction tools should be externally validated in independent cohorts before they are applied to different patient populations.
CONCLUSIONS: Predictive and prognostic tools represent valuable aids that are meant to consistently and accurately provide most evidence-based estimates of the end points of interest. More accurate, flexible, and easily accessible tools are needed to simplify the practical task of prediction.
Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20727668      PMCID: PMC4119802          DOI: 10.1016/j.eururo.2010.07.034

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  101 in total

1.  The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted.

Authors:  Umberto Capitanio; Pierre I Karakiewicz; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi
Journal:  Int J Urol       Date:  2009-03-26       Impact factor: 3.369

2.  Should I use this nomogram?

Authors:  Michael W Kattan
Journal:  BJU Int       Date:  2008-06-04       Impact factor: 5.588

3.  External validation of the updated partin tables in a cohort of French and Italian men.

Authors:  Naeem Bhojani; Laurent Salomon; Umberto Capitanio; Nazareno Suardi; Shahrokh F Shariat; Claudio Jeldres; Laurent Zini; Daniel Pharand; François Péloquin; Philippe Arjane; Claude C Abbou; Alexandre De La Taille; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-10       Impact factor: 7.038

4.  Partin Tables cannot accurately predict the pathological stage at radical prostatectomy.

Authors:  N Bhojani; S Ahyai; M Graefen; U Capitanio; N Suardi; S F Shariat; C Jeldres; A Erbersdobler; T Schlomm; A Haese; T Steuber; H Heinzer; F Montorsi; H Huland; P I Karakiewicz
Journal:  Eur J Surg Oncol       Date:  2008-09-10       Impact factor: 4.424

5.  Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best.

Authors:  Umberto Capitanio; Claudio Jeldres; Shahrokh F Shariat; Pierre Karakiewicz
Journal:  Eur Urol       Date:  2008-05-08       Impact factor: 20.096

6.  A nomogram predicting metastatic progression after radical prostatectomy.

Authors:  Christopher R Porter; Nazareno Suardi; Koichi Kodama; Umberto Capitanio; Robert P Gibbons; Roy Correa; Claudio Jeldres; Paul Perrotte; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Int J Urol       Date:  2008-07-24       Impact factor: 3.369

Review 7.  An updated catalog of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Claus G Roehrborn; Michael W Kattan
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

8.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.

Authors:  Jochen Walz; Felix K-H Chun; Eric A Klein; Alwyn Reuther; Fred Saad; Markus Graefen; Hartwig Huland; Pierre I Karakiewicz
Journal:  J Urol       Date:  2008-12-13       Impact factor: 7.450

9.  Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables.

Authors:  Kevin C Zorn; Umberto Capitanio; Claudio Jeldres; Philippe Arjane; Paul Perrotte; Shahrokh F Shariat; David I Lee; Arieh L Shalhav; Gregory P Zagaja; Sergey A Shikanov; Ofer N Gofrit; Alan E Thong; David M Albala; Leon Sun; Pierre I Karakiewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-19       Impact factor: 7.038

10.  Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Authors:  Umberto Capitanio; Pierre I Karakiewicz; Luc Valiquette; Paul Perrotte; Claudio Jeldres; Alberto Briganti; Andrea Gallina; Nazareno Suardi; Andrea Cestari; Giorgio Guazzoni; Andrea Salonia; Francesco Montorsi
Journal:  Urology       Date:  2009-02-04       Impact factor: 2.649

View more
  42 in total

Review 1.  Management of low (favourable)-risk prostate cancer.

Authors:  H Ballentine Carter
Journal:  BJU Int       Date:  2011-12       Impact factor: 5.588

2.  Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.

Authors:  Jose López-Torrecilla; Anna Boladeras; María Angeles Cabeza; Almudena Zapatero; Josep Jove; Luis M Esteban; Ivan Henriquez; Manuel Casaña; Carmen González-San Segundo; Antonio Gómez-Caamaño; Jose Luis Mengual; Asunción Hervás; Julia Luisa Muñoz; Gerardo Sanz
Journal:  Strahlenther Onkol       Date:  2015-07-09       Impact factor: 3.621

3.  Copy number alteration burden predicts prostate cancer relapse.

Authors:  Haley Hieronymus; Nikolaus Schultz; Anuradha Gopalan; Brett S Carver; Matthew T Chang; Yonghong Xiao; Adriana Heguy; Kety Huberman; Melanie Bernstein; Melissa Assel; Rajmohan Murali; Andrew Vickers; Peter T Scardino; Chris Sander; Victor Reuter; Barry S Taylor; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

4.  Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up.

Authors:  Nikolaos Grivas; Daan de Bruin; Kurdo Barwari; Erik van Muilekom; Corinne Tillier; Pim J van Leeuwen; Esther Wit; Wouter Kroese; Henk van der Poel
Journal:  J Clin Lab Anal       Date:  2018-10-26       Impact factor: 2.352

5.  Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Authors:  Bassem R Haddad; Andrew Erickson; Vindhya Udhane; Peter S LaViolette; Janice D Rone; Markku A Kallajoki; William A See; Antti Rannikko; Tuomas Mirtti; Marja T Nevalainen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-07-10       Impact factor: 4.254

Review 6.  Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Authors:  H Ballentine Carter
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

7.  Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.

Authors:  H Ballentine Carter
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 8.  [Treatment of nonmetastatic prostate cancer: a systematic review of interactive, personalized patient decision aids].

Authors:  C Groeben; J C Streuli; T Krones; B Keck; M P Wirth; J Huber
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

9.  Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.

Authors:  Stepan Vesely; Ladislav Jarolim; Marek Schmidt; Ivo Minarik; Pavel Dusek; Marko Babjuk
Journal:  World J Urol       Date:  2012-06-10       Impact factor: 4.226

Review 10.  A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting.

Authors:  Sarah J Drouin; David R Yates; Vincent Hupertan; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-18       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.